

THE PENDING CLAIMS

1-5. (Canceled)

6. (Previously Presented) A method of treating neurodegeneration in the central nervous system comprising administering a therapeutically effective amount of a chemical substance selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an optically active enantiomer or mixture of enantiomers thereof, and a pharmaceutically acceptable salt of the optically active enantiomer or mixture of enantiomers thereof to a patient having said neurodegeneration in the central nervous system.

7. (Original) A method as claimed in claim 6, wherein the chemical substance is (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.

8. (Original) A method as claimed in claim 7, wherein the chemical substance is a salt of (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.

9. (Original) A method as claimed in claim 8, wherein the chemical substance is (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate.

10. (Previously Presented) A method as claimed in any of claims 6 to 9, wherein the neurodegeneration is associated with a neurodegenerative disease selected from amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, and central nervous system neuropathies.

11. (Previously Presented) A method as claimed in claim 10, wherein the neurodegenerative disease is amyotrophic lateral sclerosis.